Identification of Candida Species and Antifungal Susceptibility in Cancer Patients with Oral Lesions in Ahvaz, Southern West of Iran

Maheronnaghsh, Mehrnoush; Fatahinia, Mahnaz; Dehghan, Parvin; Teimoori, Ali

Identification of Candida Species and Antifungal Susceptibility in Cancer Patients with Oral Lesions in Ahvaz, Southern West of Iran

Authors

¹ Infectious and Tropical Diseases Research Center, Health Research Institute; Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

² Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

³ Department of Virology, Hamedan University of Medical Sciences, Hamedan, Iran

Abstract

Background: Oral candidiasis is a common disease in cancer patients subject to chemotherapy. The aim of this study was to evaluate the risk factors of rising oral candidiasis incidence and to identify the Candida species isolated from oral lesions of cancer patients and their antifungal sensitivity. Materials and Methods: A total of 645 patients with cancer were examined. Several Candida species were isolated from specimens and identified by morphological and molecular methods. The susceptibility of isolates to amphotericin B, fluconazole, and nystatin was also investigated. Results: A total of 74 isolates of Candida were recovered from oral cavity of 61 cancer patients with oral candidiasis. The isolates included Candida albicans (n = 56; 75.5%), Candida glabrata (n = 4; 5.4%), Candida krusei (n = 5; 7%), Candida tropical (n = 7; 9.4%), and Candida kefyr (n = 2; 2.7%). A total (n = 72; 98.65%) of isolates were susceptible to nystatin, (n = 58; 78.4%) of them were susceptible to fluconazole, and (n = 8; 10.8%) of susceptible dose-dependent isolates were specified, (n = 46; 62.16%) of isolates were susceptible to amphotericin B. Conclusion: Finally, in addition to emphasis on topical nystatin application in the first stage of oral candidiasis in these patients, using alternative systemic drugs such as fluconazole and amphotericin B can be considered for the resistant candida isolates to nystatin.

Keywords

References

1.	Jackson BE, Wilhelmus KR, Hube B. The role of secreted aspartyl proteinases in Candida albicans keratitis. Invest Ophthalmol Vis Sci 2007;48:3559-65.
2.	Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010;23:253-73.
3.	Rosenbach A, Dignard D, Pierce JV, Whiteway M, Kumamoto CA. Adaptations of Candida albicans for growth in the mammalian intestinal tract. Eukaryot Cell 2010;9:1075-86.
4.	López-Martínez R. Candidosis, a new challenge. Clin Dermatol 2010;28:178-84.
5.	Odds FC. Candida and Candidosis: A Review and Bibliography. UK: Bailliere Tindall; 1988.
6.	Edwards JE Jr. Candida species. In: Mendel GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. New York: Elsevier, Churchill Livingstone; 2010.
7.	Jham BC, França EC, Oliveira RR, Santos VR, Kowalski LP, da Silva Freire AR. Candida oral colonization and infection in Brazilian patients undergoing head and neck radiotherapy: A pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:355-8.
8.	Jham BC, Reis PM, Miranda EL, Lopes RC, Carvalho AL, Scheper MA, et al. Oral health status of 207 head and neck cancer patients before, during and after radiotherapy. Clin Oral Investig 2008;12:19-24.
9.	Davies AN, Brailsford SR, Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol 2006;42:698-702.
10.	Davies AN, Brailsford SR, Beighton D, Shorthose K, Stevens VC. Oral candidosis in community-based patients with advanced cancer. J Pain Symptom Manage 2008; 35:508-14.
11.	Samaranayake LP, MacFarlane TW, Lamey PJ, Ferguson MM. A comparison of oral rinse and imprint sampling techniques for the detection of yeast, coliform and Staphylococcus aureus carriage in the oral cavity. J Oral Pathol 1986; 15:386-8.
12.	Fatahinia M, Poormohamadi F, Zarei Mahmoudabadi A. Comparative study of esterase and hemolytic important candida activities in clinically species, isolated from oral cavity of diabetic and non-diabetic individuals. Jundishapur J Microbiol 2015; 8:e20893.
13.	Kontoyiannis DP, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: An update in antifungal therapy. J Hosp Infect 2003; 53:243-58.
14.	Sydnor ER, Perl TM. Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev 2011; 24:141-73.
15.	Jahanshiri Z, Manifar S, Moosa H, Asghari-Paskiabi F, Mahmoodzadeh H, Shams-Ghahfarokhi M, et al. Oropharyngeal candidiasis in head and neck cancer patients in Iran: Species identification, antifungal susceptibility and pathogenic characterization. J Mycol Med 2018;28: 361-6.
16.	Amran F, Aziz MN, Ibrahim HM, Atiqah NH, Parameswari S, Hafiza MR, et al.In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia. J Med Microbiol 2011; 60:1312-6.
17.	Colombo AL, Da Matta D, De Almeida LP, Rosas R. Fluconazole susceptibility of Brazilian Candida isolates assessed by a disk diffusion method. Braz J Infect Dis 2002; 6:118-23.
18.	Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis. J Clin Oncol 2007; 25:5471-89.
19.	Bashir H, Ahmad J. Oral Candida colonization and infection in cancer patients and their antifungal susceptibility in a tertiary care hospital. Int J 2014; 2:541-50.
20.	Vazin A, Davarpanah MA, Ghalesoltani S. Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital. Drug Healthc Patient Saf 2015;7:97-102.
21.	Lyu X, Zhao C, Yan ZM, Hua H. Efficacy of nystatin for the treatment of oral candidiasis: A systematic review and meta-analysis. Drug Des Devel Ther 2016;10:1161-71.
22.	Orozco AS, Higginbotham LM, Hitchcock CA, Parkinson T, Falconer D, Ibrahim AS, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998;42:2645-9.
23.	Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: Pathogenicity and antifungal resistance. J Hosp Infect 2002;50:243-60.
24.	Rautemaa R, Rusanen P, Richardson M, Meurman JH. Optimal sampling site for mucosal candidosis in oral cancer patients is the labial sulcus. J Med Microbiol 2006;55:1447-51.
25.	Afraseyabi S, Afkhamzadeh A, Sabori H, Verdi F, Khaksar N, Mosavei B, et al. Oral Candidiasis amongst cancer patients at Qods hospital. Afr J Clin Exp Microbiol 2011;12;3:129-132
26.	Sroussi HY, Epstein JB, Bensadoun RJ, Saunders DP, Lalla RV, Migliorati CA, et al. Common oral complications of head and neck cancer radiation therapy: Mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med 2017;6:2918-31.
27.	Schelenz S, Abdallah S, Gray G, Stubbings H, Gow I, Baker P, et al. Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors. J Oral Pathol Med 2011;40:83-9.
28.	Dahiya MC, Redding SW, Dahiya RS, Eng TY, Kirkpatrick WR, Coco BJ, et al. Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2003;57:79-83.
29.	Kianipour S, Ardestani ME, Dehghan P. Identification of Candida albicans and Candida dubliniensis Species Isolated from bronchoalveolar lavage samples using genotypic and phenotypic methods. Adv Biomed Res 2018;7:66. [PUBMED] [Full text]
30.	Wayne P. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. NNCLS Document M27-A3. Clinical and Laboratory Standards Institute; 2008.
31.	Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Fourth Informational Supplement M27-S4. PA, USA, Wayne: Clinical and Laboratory Standards Institute; 2012.
32.	Wayne P. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard. CLSI Document M27-A2. Clinical and Laboratory Standards Institute; 2002.
33.	Katiraee F, Teifoori F, Soltani M. Emergence of azole-resistant Candida species in AIDS patients with oropharyngeal candidiasis in Iran. Curr Med Mycol 2015;1:11-6.
34.	Ostrosky-Zeichner L, Rex JH, Pfaller MA, Diekema DJ, Alexander BD, Andes D, et al. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother 2008;52:4175-7.
35.	Maheronnaghsh M, Tolouei S, Dehghan P, Chadeganipour M, Yazdi M. Identification of Candida species in patients with oral lesion undergoing chemotherapy along with minimum inhibitory concentration to fluconazole. Adv Biomed Res 2016;5:132. [PUBMED] [Full text]
36.	Al-Abeid HM, Abu-Elteen KH, Elkarmi AZ, Hamad MA. Isolation and characterization of Candida spp. in Jordanian cancer patients: Prevalence, pathogenic determinants, and antifungal sensitivity. Jpn J Infect Dis 2004;57:279-84.
37.	Kauffman CA. Candiduria. Clin Infect Dis 2005;41 Suppl 6:S371-6.
38.	Zollner-Schwetz I, Auner HW, Paulitsch A, Buzina W, Staber PB, Ofner-Kopeinig P, et al. Oral and intestinal Candida colonization in patients undergoing hematopoietic stem-cell transplantation. J Infect Dis 2008;198:150-3.
39.	Ramirez-Amador V, Silverman S Jr, Mayer P, Tyler M, Quivey J. Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:149-53.
40.	Kumar CP, Sundararajan T, Menon T, Venkatadesikalu M. Candidosis in children with onco-hematological diseases in Chennai, south India. Jpn J Infect Dis 2005;58:218-21.
41.	Ashour SM, Kheiralla Z, Maklad S, Ameen M, Zaki S. Relationship between virulence factors of Candida species with candiduria and myeloperoxidase concentrations. Int J Curr Microbiol App Sci 2015;4:108-23.
42.	Ghiasian SA, Aghamirian MR, Eshghi GR. Nosocomial candiduria in critically Ill patients admitted to intensive care units in Qazvin, Iran. Avicenna J Clin Micro Inf 2014;1(2):e21622
43.	Yu DT, Seger DL, Peterson JF, Kumar RN, Bates DW. Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. BMC Infect Dis 2006;6:173.
44.	Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: A meta-analysis of randomised-controlled trials. Br J Haematol 2005;131:22-8.
45.	Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr., Calandra TF, Edwards JE Jr., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35.
46.	Rodrigues CF, Silva S, Henriques M. Candida glabrata: A review of its features and resistance. Eur J Clin Microbiol Infect Dis 2014;33:673-88.
47.	Shokohi T, Badali H, Amirrajab N, Ataollahi MR, Kouhpayeh SA, Afsarian MH.In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran. Curr Med Mycol 2016;2:34-9.
48.	Haddadi P, Zareifar S, Badiee P, Alborzi A, Mokhtari M, Zomorodian K, et al. Yeast colonization and drug susceptibility pattern in the pediatric patients with neutropenia. Jundishapur J Microbiol 2014;7:e11858.
49.	Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett 1997;400:80-2.

Advanced Biomedical Research